TRASER: An innovative device for the treatment of nasal telangiectasias
Background Destruction of blood vessels by selective photothermolysis has been successfully achieved using a number of different laser and light systems, none of which provide significant independent variation in parameters such as wavelength. Objective To evaluate the safety and efficacy of a novel...
Gespeichert in:
| Veröffentlicht in: | Lasers in surgery and medicine 2017-08, Vol.49 (6), p.625-631 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 631 |
|---|---|
| container_issue | 6 |
| container_start_page | 625 |
| container_title | Lasers in surgery and medicine |
| container_volume | 49 |
| creator | Friedman, Paul M. Tolkachjov, Stanislav N. Geddes, Elizabeth R. Tillman, Karl A. Zachary, Christopher B. |
| description | Background
Destruction of blood vessels by selective photothermolysis has been successfully achieved using a number of different laser and light systems, none of which provide significant independent variation in parameters such as wavelength.
Objective
To evaluate the safety and efficacy of a novel configurable device in the treatment of nasal telangiectasias.
Methods
Fifteen subjects aged 42–73 with Fitzpatrick skin types I and II were treated for nasal telangiectasias of various sizes. Efficacy was measured by blinded analysis of pre and post images and self‐assessment by the subjects. The primary endpoint was a 2‐point improvement of telangiectasia based on a 5‐point Telangiectasia Scale comparing the pre‐treatment photograph to the post‐treatment photograph at 30 days post final treatment by an independent reviewer. Treatment completion was defined as >75% vessel clearance. The TRASER (Total Reflection Amplification of Spontaneous Emission Radiation) was configured to produce a narrow spectral output, peaking at 541 ± 5 nm, with 20–40 millisecond pulses over an energy density range of 15–40 J/cm2 utilizing a 12 mm spot size were delivered with contact sapphire cooling tip at approximately 10°C.
Results
All 13 subjects (100%) in the efficacy population achieved procedure success at the end of the final treatment, that is a 2‐point improvement of telangiectasis on the telangiectasia scale (pre‐ vs. post‐treatment). A single treatment was effective in >75% of patients with at least a 75% reduction in blood vessels. Larger vessels responded well to longer pulse durations (40 milliseconds) while smaller vessels responded best to shorter pulse durations (25 milliseconds). No serious adverse events (SAEs) were recorded.
Limitation
Short‐term (1 month) follow up.
Conclusion
The TRASER device is a safe and effective option for treatment of nasal telangiectasias with all subjects meeting primary endpoint success at the end of treatment and the majority of subjects demonstrating clearance after only one treatment. These treatments were well tolerated and provided high patient satisfaction. Lasers Surg. Med. 49:625–631, 2017. © 2017 Wiley Periodicals, Inc. |
| doi_str_mv | 10.1002/lsm.22651 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1884886486</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1884886486</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3531-ae3b9bb093a199a77bd4d5c3d2e77f9e44552e488851828b688519869f900d673</originalsourceid><addsrcrecordid>eNp1kEtLw0AUhQdRbK0u_AMy4EYXbeeRZGbclVKrUBHauh4myY2m5KGZSaX_3qmpLgRX9yy-ezh8CF1SMqKEsHFhyxFjUUiPUJ8SFQ0VJfQY9Qn1WRLFeujM2g0hhDMiTlGPSS6ZoKyP5uvlZDVb3uFJhfOqqrfG5VvAKWzzBHBWN9i9AXYNGFdC5XCd4cpYU2AHhalec0icsbmx5-gkM4WFi8MdoJf72Xr6MFw8zx-nk8Uw4SGnQwM8VnFMFDdUKSNEnAZpmPCUgRCZgiAIQwaBlDKkksk42gclI5UpQtJI8AG66Xrfm_qjBet0mdsECj8G6tZqKqX_jgIZefT6D7qp26by6zRVVAVEBBHz1G1HJU1tbQOZfm_y0jQ7TYne29Xerv6269mrQ2Mbl5D-kj86PTDugM-8gN3_TXqxeuoqvwBhRYD4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1919407462</pqid></control><display><type>article</type><title>TRASER: An innovative device for the treatment of nasal telangiectasias</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Friedman, Paul M. ; Tolkachjov, Stanislav N. ; Geddes, Elizabeth R. ; Tillman, Karl A. ; Zachary, Christopher B.</creator><creatorcontrib>Friedman, Paul M. ; Tolkachjov, Stanislav N. ; Geddes, Elizabeth R. ; Tillman, Karl A. ; Zachary, Christopher B.</creatorcontrib><description>Background
Destruction of blood vessels by selective photothermolysis has been successfully achieved using a number of different laser and light systems, none of which provide significant independent variation in parameters such as wavelength.
Objective
To evaluate the safety and efficacy of a novel configurable device in the treatment of nasal telangiectasias.
Methods
Fifteen subjects aged 42–73 with Fitzpatrick skin types I and II were treated for nasal telangiectasias of various sizes. Efficacy was measured by blinded analysis of pre and post images and self‐assessment by the subjects. The primary endpoint was a 2‐point improvement of telangiectasia based on a 5‐point Telangiectasia Scale comparing the pre‐treatment photograph to the post‐treatment photograph at 30 days post final treatment by an independent reviewer. Treatment completion was defined as >75% vessel clearance. The TRASER (Total Reflection Amplification of Spontaneous Emission Radiation) was configured to produce a narrow spectral output, peaking at 541 ± 5 nm, with 20–40 millisecond pulses over an energy density range of 15–40 J/cm2 utilizing a 12 mm spot size were delivered with contact sapphire cooling tip at approximately 10°C.
Results
All 13 subjects (100%) in the efficacy population achieved procedure success at the end of the final treatment, that is a 2‐point improvement of telangiectasis on the telangiectasia scale (pre‐ vs. post‐treatment). A single treatment was effective in >75% of patients with at least a 75% reduction in blood vessels. Larger vessels responded well to longer pulse durations (40 milliseconds) while smaller vessels responded best to shorter pulse durations (25 milliseconds). No serious adverse events (SAEs) were recorded.
Limitation
Short‐term (1 month) follow up.
Conclusion
The TRASER device is a safe and effective option for treatment of nasal telangiectasias with all subjects meeting primary endpoint success at the end of treatment and the majority of subjects demonstrating clearance after only one treatment. These treatments were well tolerated and provided high patient satisfaction. Lasers Surg. Med. 49:625–631, 2017. © 2017 Wiley Periodicals, Inc.</description><identifier>ISSN: 0196-8092</identifier><identifier>EISSN: 1096-9101</identifier><identifier>DOI: 10.1002/lsm.22651</identifier><identifier>PMID: 28382712</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Blood vessels ; Cooling ; Destruction ; Effectiveness ; Feasibility Studies ; Female ; Flux density ; Follow-Up Studies ; Humans ; Lasers ; Male ; Middle Aged ; Nose ; Phototherapy - instrumentation ; Phototherapy - methods ; Prospective Studies ; pulse dye laser ; pyrromethene ; Radiation ; Sapphire ; Self-assessment ; Single-Blind Method ; Skin ; Spectral emissivity ; Spontaneous emission ; telangiectasias ; Telangiectasis - therapy ; total internal reflection ; Total Reflection Amplification of Spontaneous Emission Radiation ; TRASER ; Treatment Outcome ; tunable wavelength ; variable pulse duration ; Vessels ; Young Adult</subject><ispartof>Lasers in surgery and medicine, 2017-08, Vol.49 (6), p.625-631</ispartof><rights>2017 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3531-ae3b9bb093a199a77bd4d5c3d2e77f9e44552e488851828b688519869f900d673</citedby><cites>FETCH-LOGICAL-c3531-ae3b9bb093a199a77bd4d5c3d2e77f9e44552e488851828b688519869f900d673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Flsm.22651$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Flsm.22651$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28382712$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Friedman, Paul M.</creatorcontrib><creatorcontrib>Tolkachjov, Stanislav N.</creatorcontrib><creatorcontrib>Geddes, Elizabeth R.</creatorcontrib><creatorcontrib>Tillman, Karl A.</creatorcontrib><creatorcontrib>Zachary, Christopher B.</creatorcontrib><title>TRASER: An innovative device for the treatment of nasal telangiectasias</title><title>Lasers in surgery and medicine</title><addtitle>Lasers Surg Med</addtitle><description>Background
Destruction of blood vessels by selective photothermolysis has been successfully achieved using a number of different laser and light systems, none of which provide significant independent variation in parameters such as wavelength.
Objective
To evaluate the safety and efficacy of a novel configurable device in the treatment of nasal telangiectasias.
Methods
Fifteen subjects aged 42–73 with Fitzpatrick skin types I and II were treated for nasal telangiectasias of various sizes. Efficacy was measured by blinded analysis of pre and post images and self‐assessment by the subjects. The primary endpoint was a 2‐point improvement of telangiectasia based on a 5‐point Telangiectasia Scale comparing the pre‐treatment photograph to the post‐treatment photograph at 30 days post final treatment by an independent reviewer. Treatment completion was defined as >75% vessel clearance. The TRASER (Total Reflection Amplification of Spontaneous Emission Radiation) was configured to produce a narrow spectral output, peaking at 541 ± 5 nm, with 20–40 millisecond pulses over an energy density range of 15–40 J/cm2 utilizing a 12 mm spot size were delivered with contact sapphire cooling tip at approximately 10°C.
Results
All 13 subjects (100%) in the efficacy population achieved procedure success at the end of the final treatment, that is a 2‐point improvement of telangiectasis on the telangiectasia scale (pre‐ vs. post‐treatment). A single treatment was effective in >75% of patients with at least a 75% reduction in blood vessels. Larger vessels responded well to longer pulse durations (40 milliseconds) while smaller vessels responded best to shorter pulse durations (25 milliseconds). No serious adverse events (SAEs) were recorded.
Limitation
Short‐term (1 month) follow up.
Conclusion
The TRASER device is a safe and effective option for treatment of nasal telangiectasias with all subjects meeting primary endpoint success at the end of treatment and the majority of subjects demonstrating clearance after only one treatment. These treatments were well tolerated and provided high patient satisfaction. Lasers Surg. Med. 49:625–631, 2017. © 2017 Wiley Periodicals, Inc.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Blood vessels</subject><subject>Cooling</subject><subject>Destruction</subject><subject>Effectiveness</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Flux density</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Lasers</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nose</subject><subject>Phototherapy - instrumentation</subject><subject>Phototherapy - methods</subject><subject>Prospective Studies</subject><subject>pulse dye laser</subject><subject>pyrromethene</subject><subject>Radiation</subject><subject>Sapphire</subject><subject>Self-assessment</subject><subject>Single-Blind Method</subject><subject>Skin</subject><subject>Spectral emissivity</subject><subject>Spontaneous emission</subject><subject>telangiectasias</subject><subject>Telangiectasis - therapy</subject><subject>total internal reflection</subject><subject>Total Reflection Amplification of Spontaneous Emission Radiation</subject><subject>TRASER</subject><subject>Treatment Outcome</subject><subject>tunable wavelength</subject><subject>variable pulse duration</subject><subject>Vessels</subject><subject>Young Adult</subject><issn>0196-8092</issn><issn>1096-9101</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEtLw0AUhQdRbK0u_AMy4EYXbeeRZGbclVKrUBHauh4myY2m5KGZSaX_3qmpLgRX9yy-ezh8CF1SMqKEsHFhyxFjUUiPUJ8SFQ0VJfQY9Qn1WRLFeujM2g0hhDMiTlGPSS6ZoKyP5uvlZDVb3uFJhfOqqrfG5VvAKWzzBHBWN9i9AXYNGFdC5XCd4cpYU2AHhalec0icsbmx5-gkM4WFi8MdoJf72Xr6MFw8zx-nk8Uw4SGnQwM8VnFMFDdUKSNEnAZpmPCUgRCZgiAIQwaBlDKkksk42gclI5UpQtJI8AG66Xrfm_qjBet0mdsECj8G6tZqKqX_jgIZefT6D7qp26by6zRVVAVEBBHz1G1HJU1tbQOZfm_y0jQ7TYne29Xerv6269mrQ2Mbl5D-kj86PTDugM-8gN3_TXqxeuoqvwBhRYD4</recordid><startdate>201708</startdate><enddate>201708</enddate><creator>Friedman, Paul M.</creator><creator>Tolkachjov, Stanislav N.</creator><creator>Geddes, Elizabeth R.</creator><creator>Tillman, Karl A.</creator><creator>Zachary, Christopher B.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201708</creationdate><title>TRASER: An innovative device for the treatment of nasal telangiectasias</title><author>Friedman, Paul M. ; Tolkachjov, Stanislav N. ; Geddes, Elizabeth R. ; Tillman, Karl A. ; Zachary, Christopher B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3531-ae3b9bb093a199a77bd4d5c3d2e77f9e44552e488851828b688519869f900d673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Blood vessels</topic><topic>Cooling</topic><topic>Destruction</topic><topic>Effectiveness</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Flux density</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Lasers</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nose</topic><topic>Phototherapy - instrumentation</topic><topic>Phototherapy - methods</topic><topic>Prospective Studies</topic><topic>pulse dye laser</topic><topic>pyrromethene</topic><topic>Radiation</topic><topic>Sapphire</topic><topic>Self-assessment</topic><topic>Single-Blind Method</topic><topic>Skin</topic><topic>Spectral emissivity</topic><topic>Spontaneous emission</topic><topic>telangiectasias</topic><topic>Telangiectasis - therapy</topic><topic>total internal reflection</topic><topic>Total Reflection Amplification of Spontaneous Emission Radiation</topic><topic>TRASER</topic><topic>Treatment Outcome</topic><topic>tunable wavelength</topic><topic>variable pulse duration</topic><topic>Vessels</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Friedman, Paul M.</creatorcontrib><creatorcontrib>Tolkachjov, Stanislav N.</creatorcontrib><creatorcontrib>Geddes, Elizabeth R.</creatorcontrib><creatorcontrib>Tillman, Karl A.</creatorcontrib><creatorcontrib>Zachary, Christopher B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Lasers in surgery and medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Friedman, Paul M.</au><au>Tolkachjov, Stanislav N.</au><au>Geddes, Elizabeth R.</au><au>Tillman, Karl A.</au><au>Zachary, Christopher B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TRASER: An innovative device for the treatment of nasal telangiectasias</atitle><jtitle>Lasers in surgery and medicine</jtitle><addtitle>Lasers Surg Med</addtitle><date>2017-08</date><risdate>2017</risdate><volume>49</volume><issue>6</issue><spage>625</spage><epage>631</epage><pages>625-631</pages><issn>0196-8092</issn><eissn>1096-9101</eissn><abstract>Background
Destruction of blood vessels by selective photothermolysis has been successfully achieved using a number of different laser and light systems, none of which provide significant independent variation in parameters such as wavelength.
Objective
To evaluate the safety and efficacy of a novel configurable device in the treatment of nasal telangiectasias.
Methods
Fifteen subjects aged 42–73 with Fitzpatrick skin types I and II were treated for nasal telangiectasias of various sizes. Efficacy was measured by blinded analysis of pre and post images and self‐assessment by the subjects. The primary endpoint was a 2‐point improvement of telangiectasia based on a 5‐point Telangiectasia Scale comparing the pre‐treatment photograph to the post‐treatment photograph at 30 days post final treatment by an independent reviewer. Treatment completion was defined as >75% vessel clearance. The TRASER (Total Reflection Amplification of Spontaneous Emission Radiation) was configured to produce a narrow spectral output, peaking at 541 ± 5 nm, with 20–40 millisecond pulses over an energy density range of 15–40 J/cm2 utilizing a 12 mm spot size were delivered with contact sapphire cooling tip at approximately 10°C.
Results
All 13 subjects (100%) in the efficacy population achieved procedure success at the end of the final treatment, that is a 2‐point improvement of telangiectasis on the telangiectasia scale (pre‐ vs. post‐treatment). A single treatment was effective in >75% of patients with at least a 75% reduction in blood vessels. Larger vessels responded well to longer pulse durations (40 milliseconds) while smaller vessels responded best to shorter pulse durations (25 milliseconds). No serious adverse events (SAEs) were recorded.
Limitation
Short‐term (1 month) follow up.
Conclusion
The TRASER device is a safe and effective option for treatment of nasal telangiectasias with all subjects meeting primary endpoint success at the end of treatment and the majority of subjects demonstrating clearance after only one treatment. These treatments were well tolerated and provided high patient satisfaction. Lasers Surg. Med. 49:625–631, 2017. © 2017 Wiley Periodicals, Inc.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28382712</pmid><doi>10.1002/lsm.22651</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0196-8092 |
| ispartof | Lasers in surgery and medicine, 2017-08, Vol.49 (6), p.625-631 |
| issn | 0196-8092 1096-9101 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1884886486 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adolescent Adult Aged Blood vessels Cooling Destruction Effectiveness Feasibility Studies Female Flux density Follow-Up Studies Humans Lasers Male Middle Aged Nose Phototherapy - instrumentation Phototherapy - methods Prospective Studies pulse dye laser pyrromethene Radiation Sapphire Self-assessment Single-Blind Method Skin Spectral emissivity Spontaneous emission telangiectasias Telangiectasis - therapy total internal reflection Total Reflection Amplification of Spontaneous Emission Radiation TRASER Treatment Outcome tunable wavelength variable pulse duration Vessels Young Adult |
| title | TRASER: An innovative device for the treatment of nasal telangiectasias |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T11%3A28%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TRASER:%20An%20innovative%20device%20for%20the%20treatment%20of%20nasal%20telangiectasias&rft.jtitle=Lasers%20in%20surgery%20and%20medicine&rft.au=Friedman,%20Paul%20M.&rft.date=2017-08&rft.volume=49&rft.issue=6&rft.spage=625&rft.epage=631&rft.pages=625-631&rft.issn=0196-8092&rft.eissn=1096-9101&rft_id=info:doi/10.1002/lsm.22651&rft_dat=%3Cproquest_cross%3E1884886486%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1919407462&rft_id=info:pmid/28382712&rfr_iscdi=true |